This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine

Motley Fool2021-08-03

In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Sogon
2021-08-03
Sogon
Wow
- chiapopo:
  Oh yes [害羞] [害羞]
Totoroido
2021-08-03
Totoroido
Cool
SeC
2021-08-03
SeC
Like and comment pls. Thanks
- diamondHands:
  done
Sanushks
2021-08-03
Sanushks
finally!
HENRYCSC
2021-08-03
HENRYCSC
?
Ping2joseph
2021-08-03
Ping2joseph
Nice

Leave a comment

174

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2156147918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-03 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2156147918","market":"us","top_or_hot":-1,"title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","media":"Motley Fool","content":"<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","article_id":"2156147918","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","pubTimestamp":1627994460,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Pfizer might not have to wait very long for this product to hit the market.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"这可能是辉瑞的下一部COVID大片--它不是疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9},"content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","kind":"highlight","is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":807344847,"gmtCreate":1628002694689,"gmtModify":1703499508798,"author":{"id":"3574595664255534","authorId":"3574595664255534","name":"Sogon","avatar":"https://static.tigerbbs.com/5f976e066a7b05d035ba174a06f3d8eb","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3574595664255534","idStr":"3574595664255534"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807344847","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5421223,"gmtCreate":1628048774897,"gmtModify":1663231905427,"authorId":3554640535164305,"author":{"id":3554640535164305,"idStr":"3554640535164305","authorId":3554640535164305,"name":"chiapopo","avatar":"https://static.tigerbbs.com/2957ce010338093c9faf4ac1d533b533","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":807344847,"type":1,"supId":0,"prevId":0,"content":"Oh yes  [害羞] [害羞]","text":"Oh yes  [害羞] [害羞]","html":"Oh yes  [害羞] [害羞]"}],"langContent":"EN"},{"id":807350217,"gmtCreate":1628001719339,"gmtModify":1703499484870,"author":{"id":"4087537620314880","authorId":"4087537620314880","name":"Totoroido","avatar":"https://static.tigerbbs.com/9d6f731ba4e6c392e51172cb7506f447","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087537620314880","idStr":"4087537620314880"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807350217","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":807336621,"gmtCreate":1627999859563,"gmtModify":1703499420166,"author":{"id":"3582371848241817","authorId":"3582371848241817","name":"SeC","avatar":"https://static.tigerbbs.com/a226cf90d6854e9178341c90697ce373","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582371848241817","idStr":"3582371848241817"},"htmlText":"Like and comment pls. Thanks","listText":"Like and comment pls. Thanks","text":"Like and comment pls. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/807336621","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5415793,"gmtCreate":1628001268484,"gmtModify":1663231879343,"authorId":3573553598754980,"author":{"id":3573553598754980,"idStr":"3573553598754980","authorId":3573553598754980,"name":"diamondHands","avatar":"https://static.tigerbbs.com/dc04e09561a7a5cf929c1ad9f33b1d82","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":807336621,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":807397788,"gmtCreate":1627999674144,"gmtModify":1703499413372,"author":{"id":"3578876287370038","authorId":"3578876287370038","name":"Sanushks","avatar":"https://static.tigerbbs.com/79979e3e99c551c0a42857db491f804c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3578876287370038","idStr":"3578876287370038"},"htmlText":"finally!","listText":"finally!","text":"finally!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807397788","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":807394900,"gmtCreate":1627999604200,"gmtModify":1703499410775,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3575091428590185","idStr":"3575091428590185"},"htmlText":"?&nbsp;","listText":"?&nbsp;","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807394900","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":807307071,"gmtCreate":1627999298493,"gmtModify":1703499399504,"author":{"id":"3578387522492131","authorId":"3578387522492131","name":"Ping2joseph","avatar":"https://community-static.tradeup.com/news/1485b66e7cf5b8745bdd93307ea27e55","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3578387522492131","idStr":"3578387522492131"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/807307071","repostId":2156147918,"repostType":4,"repost":{"id":"2156147918","kind":"highlight","pubTimestamp":1627994460,"share":"https://ttm.financial/m/news/2156147918?lang=&edition=fundamental","pubTime":"2021-08-03 20:41","market":"us","language":"en","title":"This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2156147918","media":"Motley Fool","summary":"Pfizer might not have to wait very long for this product to hit the market.","content":"<p>In 2019 and 2020,&nbsp;<b>Pfizer</b>'s (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.</p>\n<p>But Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and <b>BioNTech</b> (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.</p>\n<p>Even more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.</p>\n<p><img src=\"https://static.tigerbbs.com/2e39eb3485964eb8dab974f72921be8b\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Stopping the coronavirus in its tracks</h3>\n<p>Pfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on <a href=\"https://laohu8.com/S/AONE.U\">one</a> especially promising therapy in its second-quarter conference call last week.</p>\n<p>Protease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.</p>\n<p>Pfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.</p>\n<p>Chief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"</p>\n<p>So far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.</p>\n<p>Based on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.</p>\n<h3>A big market opportunity</h3>\n<p>Pfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.</p>\n<p>The U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to <b>Regeneron</b>'s (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.</p>\n<p>First, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.</p>\n<p>Pfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.</p>\n<h3>Coming soon?</h3>\n<p>There shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.</p>\n<p>Pfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"</p>\n<p>PF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Could Be Pfizer's Next COVID Blockbuster -- and It Isn't a Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-03 20:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/08/03/this-could-be-pfizers-next-covid-blockbuster-and-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156147918","content_text":"In 2019 and 2020, Pfizer's (NYSE:PFE) top-selling product was pneumococcal vaccine Prevnar 13. It generated over $5.8 billion in sales in both years. That's a lot of money for a very successful product.\nBut Prevnar 13 is no longer Pfizer's top-selling product. The COVID-19 vaccine BNT162b2, developed by Pfizer and BioNTech (NASDAQ:BNTX), generated sales of $7.8 billion in the first half of 2021 alone. Pfizer expects the vaccine will rake in $33.5 billion over the entire year. Even with the company splitting profits with BioNTech, Pfizer should conservatively make in the ballpark of $17 billion from BNT162b2 this year.\nEven more money could be on the way. Pfizer is busy working on its next potential COVID-19 blockbuster -- and it isn't a vaccine.\n\nImage source: Getty Images.\nStopping the coronavirus in its tracks\nPfizer has stated for a while that it wouldn't restrict its efforts to fight COVID-19 to only vaccines. It has also focused on developing potential treatments for the infectious disease. The company provided an update on one especially promising therapy in its second-quarter conference call last week.\nProtease inhibitors are a class of antiviral drugs that have been effective in treating HIV and hepatitis C. These therapies bind to protease enzymes in viruses and prevent the virus from replicating.\nPfizer initiated an early stage clinical study evaluating oral protease inhibitor PF-07321332 in March of this year. The company had good news to report from that study in its Q2 update.\nChief scientific officer Mikael Dolsten said that in the phase 1 study, PF-07321332 exceeded the level predicted to inhibit coronavirus viral replication by more than fivefold. Dolsten also stated that the experimental protease inhibitor showed powerful antiviral activity in preclinical testing that could be effective against \"all currently known COVID-19 variants.\"\nSo far, the experimental antiviral drug appears to have a good safety profile. Dolsten said that there haven't been any safety issues in giving doses of up to 500 milligrams twice per day over a 10-day period.\nBased on these encouraging results, Pfizer advanced the oral protease inhibitor into phase 2/3 testing in July. The company will evaluate PF-07321332 in five-day and 10-day treatments for individuals who have been in close contact with someone with COVID-19.\nA big market opportunity\nPfizer estimates that the addressable market for its protease inhibitor could be in the hundreds of millions of patients. That doesn't seem farfetched considering the rapid spread of COVID-19 exposure due to the delta variant.\nThe U.S. Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) to Regeneron's (NASDAQ:REGN) antibody cocktail REGEN-COV as a treatment for hospitalized COVID-19 patients and for post-exposure prophylaxis. However, there are a few drawbacks to Regeneron's therapy.\nFirst, REGEN-COV is expensive -- more than $2,000 per dose. Second, it must be administered via infusion or subcutaneous injection. Third, the current U.S. EUA for post-exposure prophylaxis only applies to individuals who have been exposed to COVID-19 who have a high risk of developing COVID-19 and who haven't been fully vaccinated.\nPfizer's PF-07321332 would be much more convenient than REGEN-COV since it's taken orally. Although the big drugmaker hasn't given any hints about what the pricing for the antiviral therapy might be should it win EUA or approval, a lower price tag could open up a wide market that might include lower-risk individuals who are exposed to COVID-19.\nComing soon?\nThere shouldn't be a long wait for Pfizer's next potential COVID-19 blockbuster. Assuming the phase 2/3 testing goes well, the company thinks that it will be able to file for U.S. EUA in the fourth quarter of this year.\nPfizer CEO Albert Bourla said in the company's Q2 call that he's given the green light to manufacture \"significant quantities\" of the oral protease inhibitor so that large volumes of doses will be available if EUA is granted. He added that Pfizer is absorbing the risk of making this investment because \"it is the right thing to do.\"\nPF-07321332 probably won't be as big a catalyst for the big pharma stock as the Pfizer-BioNTech COVID-19 vaccine. However, Pfizer won't have to split the profits on the oral therapy as it does with BNT162b2. If the company's late-stage testing of the COVID-19 drug is successful, Pfizer seems very likely to have another blockbuster on its hands in 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":174,"commentSize":33,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2156147918"}